Celentyx was founded upon applied research originating from the world-renowned Medical Research Council (UK) Centre for Immune Regulation, situated in the University of Birmingham Medical School.
The founders, Professor Nicholas Barnes and Professor John Gordon were amongst the first to recognise that many neurotransmitters also modify the immune system and are internationally recognised authorities in this relatively new field of neuroimmunopharmacology. Their development of Immuno-Profiling™ provides an efficient low risk drug discovery strategy.
The platform technology uses human isolated tissues and cells and has already led to the discovery of two drug candidates ready to enter Phase II clinical trial; one for the treatment of various forms of non-Hodgkin’s lymphoma (NHL is now considered the fifth most common of all cancers) and the other for the treatment of a prevalent form of epilepsy that characteristically is refractory to current medication.
In addition to utilising Immuno-Profiling™ to identify its own drug candidates, Celentyx also offers other pharmaceutical companies access to Immuno-Profiling™ to reprofile NCEs and biologicals for immune disorders, to elucidate mechanism of action at the molecular and cellular level and also predict adverse reactions mediated via human immune system prior to first administration to man.